Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$52.10 USD
-0.36 (-0.69%)
Updated Jun 13, 2024 04:00 PM ET
Pre-Market: $51.35 -0.75 (-1.44%) 9:26 AM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Brokerage Reports
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 41 - 60 ( 212 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Three Data Shots on Goal With VOYAGE Leading Charge; Reiterate 2023 Top Pick
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HCW 2023 Top Picks: Seize the Opportunities
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK2809 Prepping For NASH Top-Line Data Readout in 1H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Great Readthrough For VK2809; Phase 2b VOYAGE Readout Anticipated 1H23; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; Time''s a Comin''; Critical Data Readouts Expected by 1H23; Reit. Buy and $21 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Recap - Enrollment Completion Expected by Year-End
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q22 Results; Three-Pronged Approach Advances; Multiple Data Readouts in Next 12 Months
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK0124 Clinical Program Gets FDA Nod to Restart; Pushing Toward Key VK2809 Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Results; Clinical Programs Continue to Advance; VK2809 and VK2735 Updates Expected by Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Recap - Enrollment Completion Targeted for 2H22
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2021 Results; Focus on VOYAGE End Game and Pipeline Visibility This Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Confidence Around VK2809''s MoA Swells Ahead of VOYAGE; Top Line Data in 2H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J